Pipeline developments include:-New diabetes treatment ONGLYZATM approved in the US and the European Union.-Brilinta submitted for regulatory approval in the European Union; on track for US submission in the fourth quarter.-New late stage development collaborations announced with Forest Laboratories and Nektar Therapeutics.-Regulatory submissions for Zactima have been withdrawn, based upon an updated analysis that demonstrated no overall survival advantage when added to chemotherapy.

Core EPS target for the full year increased to range of $6.20 to $6.40.

Financial Summary [See links for tables: feed.ne.cision/wpyfs/00/00/00/00/00/0F/EA/23/wkr0011.pdf, feed.ne.cision/wpyfs/00/00/00/00/00/0F/EA/24/wkr0013.pdf]

David Brennan, Chief Executive Officer, said: Our strong business performance is driven by good operating execution bolstered by revenue upsides from Toprol-XL and H1N1 vaccine sales. All these factors are reflected in our results for the first nine months and our increased Core EPS target for the full year. Since the half year we have made progress on the pipeline with the approval of ONGLYZATM, the European submission for Brilinta and new external collaborations, tempered by the disappointing news on Zactima.

cisionwire